In vitro and in vivo human metabolism of the synthetic cannabinoid AB-CHMINACA

Drug Testing and Analysis

Volumn 7, Issue 10, 2015, Pages 866-876

  Erratico, Claudio ^a   Negreira, Noelia ^a   Norouzizadeh, Helia ^a   Covaci, Adrian ^a   Neels, Hugo ^a   Maudens, Kristof ^a   van Nuijs, Alexander L N ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

AB CHMINACA; Human liver microsomes; In vitro metabolism; LC QTOF MS

Indexed keywords

BIOMOLECULES; BODY FLUIDS; ENZYMES; HYDROXYLATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITES; PHYSIOLOGY;

AB-CHMINACA; BIOMONITORING STUDIES; HUMAN LIVER MICROSOMES; HUMAN METABOLISMS; IN VITRO METABOLISM; IN-VITRO; IN-VIVO; LC-Q-TOF MS; SYNTHETIC CANNABINOID; VITRO AND IN VIVO;

METABOLISM;

CANNABINOID; CYTOCHROME P450; N [1 (AMINOCARBONYL) 2 METHYLPROPYL] 1 (CYCLOHEXYLMETHYL) 1H INDAZOLE 3 CARBOXAMIDE; UNCLASSIFIED DRUG; DESIGNER DRUG; INDAZOLE DERIVATIVE; N-(1-(AMINOCARBONYL)-2-METHYLPROPYL)-1-(CYCLOHEXYLMETHYL)-1H-INDAZOLE-3-CARBOXAMIDE; VALINE;

ANALYTIC METHOD; ARTICLE; BIOLOGICAL MONITORING; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; METABOLISM; METABOLITE; PRIORITY JOURNAL; TIME OF FLIGHT MASS SPECTROMETRY; ANALOGS AND DERIVATIVES; CHEMISTRY; HYDROXYLATION; MASS SPECTROMETRY;

CANNABINOIDS; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DESIGNER DRUGS; HUMANS; HYDROXYLATION; INDAZOLES; MASS SPECTROMETRY; MICROSOMES, LIVER; VALINE;

EID: 84943450461     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1796     Document Type: Article

References (34)

1. United Nations Office on Drugs and Crime. The Challenge of New Psychoactive Substances, A Report from the Global SMART Programme. United Nations Office of Drugs and Crime, Vienna, Austria, 2013.
2. European Monitoring Center for Drugs and Drug Addiction (EMCDDA). Perspectives on drugs: Synthetic cannabinoids in Europe. Available at http://www.emcdda.europa.eu/attachements.cfm/att_212361_EN_EMCDDA_POD_2013_Synthetic%20cannabinoids.pdf [3 February 2015].
3. B. K. Atwood, J. Huffman, A. Straiker, K. Mackie. JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Brit. J. Pharmacol. 2010, 160, 585.
4. L. K. Brents, E. E. Reichard, S. M. Zimmerman, J. H. Moran, W. E. Fantegrossi, P. L. Prather. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One. 2011, 6, e21917.
5. S. J. Ward, E. Baizman, M. Bell, S. Childers, T. D'Ambra, M. Eissenstat, K. Estep, D. Haycock, A. Howlett, D. Luttinger. Aminoalkylindoles (AAIs): A new route to the cannabinoid receptor? NIDA Res. Monogr. 1990, 105, 425.
6. G. A. Thakur, S. P. Nikas, A. Makriyannis. CB1 cannabinoid receptor ligands. Mini Rev. Med. Chem. 2005, 5, 631.
7. R. N. Kumar, W. A. Chambers, R. G. Pertwee. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. 2001, 56, 1059.
8. S. Tai, W. E. Fantegrossi. Synthetic cannabinoids: Pharmacology, behavioral effects, and abuse potential. Curr. Addict. Rep. 2014, 1, 129.
9. R. Kikura-Hanajiri, N. Uchiyama, M. Kawamura, Y. Godo. Changes in the prevalence of new psychoactive substances before and after the introduction of the generic scheduling of synthetic cannabinoids in Japan. Drug Test. Anal. 2014, 6, 832.
10. N. Uchiyama, Y. Shimokawa, M. Kawamura, R. Kikura-Hanajiri, T. Hakamatsuka. Chemical analysis of a benzofuran derivative, 2-(2-ethylaminopropyl)benzofuran (2-EAPB), eight synthetic cannabinoids, five cathinone derivatives, and five other designer drugs newly detected in illegal products. Forensic Toxicol. 2014, 32, 266.
11. N. Uchiyama, S. Matsuda, D. Wakana, R. Kikura-Hanajiri, Y. Goda. New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products. Forensic Toxicol. 2013, 31, 93.
12. K. Hasegawa, A. Wurita, K. Minakata, K. Gonmori, H. Nozawa, I. Yamagishi, K. Watanabe, O. Suzuki. Postmortem distribution of AB-CHMINACA, 5-fluoro-AMB, and diphenidine in body fluids and solid tissues in a fatal poisoning case: usefulness of adipose tissue for detection of the drugs in unchanged forms. Forensic Toxicol. 2015, 33, 45.
13. Drug Enforcement Administration, U.S. Department of Justice. Schedules of Controlled Substances: Temporary Placement of Three Synthetic Cannabinoids Into Schedule I. Fed. Regist. 2014, 79, 75767. Available at: http://www.deadiversion.usdoj.gov/fed_regs/rules/2014/fr1219.htm [3 February 2015].
14. R. Thomsen, L.M. Nielsen, N.B. Holm, H.B. Rasmussen, K. Linnet. The INDICES consortium. Synthetic cannabimimetic agents metabolized by carboxylesterases. Drug Test. Anal. DOI: 10.1002/dta.1731
15. T. Takayama, M. Suzuki, K. Todoroki, K. Inoue, J. Z. Min, R. Kikura-Hanajiri, Y. Goda, T. Toyo'oka. UPLC/ESI-MS/MS-based determination of metabolism of several new illict drugs, ADB-FUBINACA, AB-FUBINACA, AB-PINACA, QUPIC, 5F-QUPIC and α-PVT, by human liver microsomes. Biomed. Chromatogr. 2014, 28, 831.
16. Y. H. Zhao, J. Le, M. H. Abraham, A. Hersey, P. J. Eddershaw, C. N. Luscombe, D. Butina, G. Beck, B. Sherborne, I. Cooper, J. A. Platts. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the abraham escriptors. J. Pharm. Sci. 2001, 90, 749.
17. V. Subrahmanyam, A. B. Renwick, D. G. Walters, P. J. Young, R. J. Price, A. P. Tonelli, B. G. Lake. Identification of cytochrome P-450 isoforms responsible for cis-tradamdol metabolism in human liver microsomes. Drug Metab. Dispos. 2001, 29, 1146.
18. R. H. Tukey, C. P. Strassburg. Human UDP-glucuronosyltransferases: Metabolism, expression and diseases. Ann. Rev. Toxicol. 2000, 40, 581.
19. U. A. Argikar. Unusual glucuronides. Drug Metab. Dispos. 2012, 40, 1239.
20. W. E. Gall, G. Zawada, B. Mojarrabi, T. R. Tephly, M. D. Green, B. L. Coffman, P. I. Mackenzie, A. Radominska-Pandya. Differential glucuronidation of bile acids, androgens and estrogens by human UGT1A3 and 2B7. J. Ster. Mol. Biol. 1999, 70, 101.
21. J. Hasegawa, P. C. Smith, L. Z. Benet. Apparent intramolecular acyl migration of zomepirac glucuronide. Drug Metab. Dispos. 1982, 10, 469.
22. R. W. Mortensen, U. G. Sidelmann, J. Tjornelund, S. H. Hansen. Stereospecific pH-dependent degradation kinetics of R- and S-naproxen-beta-l-Oacyl- glucuronide. Chirality. 2002, 14, 305.
23. M. J. Jin, J. Lee, M. K. In, H. H. Yoo. Characterization of in vitro metabolites of CP 47, 497, a synthetic cannabinoid, in human liver microsomes by LC-MS/MS. J. Forensic Sci. 2013, 58, 195.
24. A. S. Gandhi, M. Zhu, S. Pang, A. Wohlfarth, K. B. Scheidweiler, H. F. Liu, M. A. Huestis. First characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry. AAPS J. 2013, 15, 1091.
25. A. Wohlfarth, A. S. Gandhi, S. Pang, M. Zhu, K. B. Scheidweiler, M. A. Huestis. Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. Anal. Bioanal. Chem. 2014, 406, 1763.
26. T. Sobolevsky, I. Prasolov, G. Rodchenkov. Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids. Drug Test. Anal. 2012, 4, 745.
27. A. Wintermeyer, I. Möller, M. Thevis, M. Jübner, J. Beike, M. A. Rothschild, K. Bender. In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal. Bioanal. Chem. 2010, 398, 2141.
28. A. Wohlfarth, S. Pang, M. Zhu, A. S. Gandhi, K. B. Scheidweiler, H. F. Liu, M. A. Huestis. First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. Clin. Chem. 2013, 59, 1638.
29. K. C. Chimalakonda, K. A. Seely, S. M. Bratton, L. K. Brents, C. L. Moran, G. W. Endres, L. P. James, P. F. Hollenberg, P. L. Prather, A. Radominska-Pandya, J. H. Moran. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/spice: Identification of novel cannabinoid receptor ligands. Drug Metab. Dispos. 2012, 40, 2174.
30. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, F. P. Guengerich. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994, 270, 414.
31. M. F. Paine, H. L. Hart, S. S. Ludington, R. L. Haining, A. E. Rettie, D. C. Zeldin. The human intestinal cytochrome P450 "pie". Drug Metab. Dispos. 2006, 34, 880.
32. S. A. Wrighton, W. R. Brian, M. A. Sari, M. Iwasaki, F. P. Guengerich, J. L. Raucy, D. T. Molowa, M. Vandenbranden. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 1990, 38, 207.
33. F.P. Guengerich. in Cytochrome P450: Structure, Mechanism and Biochemistry. (Ed: P.R.O. de Montellano), Kluwer Academic and Plenum Publishers, New York, 2005, pp.377-463.
34. H. Yamazaki, T. Shimada. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch. Biochem. Biophys. 1997, 346, 161.